frame-graph02ttt01Overall1.800.20.40.60.811.21.41.6PlaceboXyzalP<0.001Improvement in RQLQQoL_Chart1_All_m[1]OverallPlaceboXyzalP<0.0011.800.20.40.60.811.21.41.6Improvement in RQLQ37%improvementvs placebo (P<0.001)Vector Smart ObjectNasalSymptomsEyeSymptoms**PlaceboXyzal*P<0.001;P<0.051.800.20.40.60.811.21.41.6Improvement in RQLQQoL_Chart1_All_m[1]*P<0.001;P<0.05PlaceboXyzalNasalSymptomsEyeSymptoms**1.800.20.40.60.811.21.41.6Improvement in RQLQVector Smart Object2ActivitiesSleepPracticalProblemsEmotional**PlaceboXyzal*P<0.001;P<0.051.800.20.40.60.811.21.41.6Improvement in RQLQQoL_Chart1_All_m[1]ActivitiesSleepPracticalProblemsEmotional**1.800.20.40.60.811.21.41.6*P<0.001;P<0.05PlaceboXyzalImprovement in RQLQttt02Improvement in WPAI-AS Scores20181614121086420Patient Xperience20181614121086420ctaObject1LevocetirizineXyzalvs.LevocetirizineXyzal 5 mgLevocetirizineDextrocetirizineZyrtec 10 mgvs.Xyzal 5 mgLevocetirizineDextrocetirizineZyrtec 10 mgLevocetirizinesymptom-xpert-graph00-desktop-50-40-30-20-100Xyzal(n=240)Xyzal(n=236)!"!#!$!"#$()*+,-./,01-50-40-30-20-100Percent Reduction in MSCS with XyzalXyzal(n=240)Xyzal(n=236)46%reduction vs 11% placebo (n=93) (P<0.001)34% reduction vs 18% placebo (n=95) (P<0.001)Hour 1Hour 24Week 8Mean T4SS Change from BaselineWeek 10-0.5-1-1.5-2-2.5-3-3.5-4PlaceboXyzalVector Smart Object4PlaceboXyzalWeek 1Week 80-0.5-1-1.5-2-2.5-3-3.5-486%Reductionvs placebo(P<0.001)47%Reductionvs placebo(P<0.001)Mean T4SS Change from Baseline0 -0.5 -1 -1.5 -2 -2.5 -3 -3.5 -4symptom-xpert-graph02-desktopWeek 100.20.40.60.81.06 MonthsMean T5SS Change from BaselineXyzalPlacebo6 MonthsWeek 1PlaceboXyzal00.20.40.60.81.06 MonthsMean T5SS Change from BaselineWeek 16 Months00.20.40.60.81.0PlaceboXyzalMean T5SS Change from BaselineWeek 16 MonthsPlaceboXyzal00.20.40.60.81.0Mean T5SS Change from BaselineWeek 16 MonthsPlaceboXyzal00.20.40.60.81.0Mean T5SS Change from BaselineSignificant Reduction in Symptoms14121086420-2-101 25 26 27 28Mean Score (MSCS)24PlaceboXyzal 5 mg (P<0.001)Hours After Drug IntakeSignificant Reduction in Symptoms

For U.S. Healthcare Professionals Only

Potent proof that not all OTC oral
antihistamines
are built the same

Xyzal is the active enantiomer 
of Zyrtec, delivering 2x the
binding affinity with none of 
the dextrocetirizine1,2

The Xyzal Molecule

Levocetirizine + No Dextrocetirizine

The Zyrtec Molecule

Levocetirizine + Dextrocetirizine
Active enantiomer of Zyrtec with no dextrocetirizine
Active enantiomer of Zyrtec with no dextrocetirizine
Xyzal contains levocetirizine, the active enantiomer thought to provide the therapeutic antihistamine effect in Zyrtec. Its antihistaminic effects are mediated via high selectivity
of the H1 receptor.1-3
Xyzal contains no dextrocetirizine, which has
a 5.5x higher distribution
across the blood-brain barrier than levocetirizine.4,*


The clinical relevance regarding the absence of dextrocetirizine is unknown.

Learn how Xyzal can impact
patients' everyday lives
Learn how Xyzal can impact patient's everyday lives
Footnotes & References
x
  • *As demonstrated in an in vivo study comparing 3 different tissue-to-plasma partition coefficients: Kp, Kp,u, and Kp,uu.
  • References: 1. Xyzal [prescribing information]. Smyrna, GA: UCB, Inc.; 2016. 2. Tillement J-P, Testa B, Brée F. Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. Biochem Pharmacol. 2003;66(7):1123-1126. 3. Data on file, sanofi-aventis U.S. LLC. 4. Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M. Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: Kp, Kp,u, and Kp,uu. Drug Metab Dispos. 2006;34(2):318-323.

Xyzal works differently from other oral antihistamines

Xyzal pharmacologic profile vs other OTC oral antihistamines1,2,a
Xyzal allergy 24hr

Stronger H1
receptor
binding vs:

Xyzal allergy 24hr

Faster time
to tmax vsb:

Xyzal allergy 24hr

Longer
duration of
action vs:

Xyzal allergy 24hr

Lower
volume of
distribution vs:

  • Zyrtec
  • Allegra
  • Claritin
  • Claritin
  • Benadryl
  • Benadryl
  • Allegra
  • Claritin

The clinical relevance of these findings is unknown.

aBased on labeled dosing.
bBased on first dose only. Tmax does not always equate to onset action.

Footnotes & References
x
  • Allegra®, Benadryl®, Claritin®, and Zyrtec® are registered trademarks of their respective owners. See individual product packaging for information about use.
  • References: 1. Canonica GW, Blaiss M. Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J. 2011;4:47-53. 2. del Cuvillo A, Mullol J, Bartra J, et al. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16(suppl 1):3-12.

Xyzal delivers
efficacy in a 5 mg tablet1,2

For illustrative purposes only.


The clinical relevance regarding the
absence of dextrocetirizine is unknown.

Footnotes & References
x
  • References: 1. Xyzal [prescribing information]. Smyrna, GA: UCB, Inc.; 2016. 2. Zyrtec [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; sanofi-aventis; 2002.

Xyzal Allergy 24HR dosing, same as
prescription-strength Xyzal

Xyzal Allergy 24HR
Adults 65 years of age and older
  • Ask a doctor
Adults and children 12-64 years of age
  • Take 1 tablet (5 mg) once daily in the evening
  • Do not take more than 1 tablet (5 mg) in 24 hours
  • ½ tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms
Children 6-11 years of age
  • Take ½ tablet (2.5 mg) once daily in the evening
  • Do not take more than ½ tablet (2.5 mg) in 24 hours
Children under 6 years of age
  • Do not use
Consumers with kidney disease
  • Do not use

Use as directed; see full Drug Facts label.

Children's Xyzal Allergy 24HR Oral Solution
Adults 65 years of age and older
  • Ask a doctor
Adults and children 12-64 years of age
  • Take 5 mL or 10 mL once daily in the evening depending upon severity of symptoms
  • Do not take more than 10 mL in 24 hours
Children 6-11 years of age
  • Take 5 mL once daily in the evening
  • Do not take more than 5 mL in 24 hours
Children 2-5 years of age
  • Take 2.5 mL once daily in the evening
  • Do not take more than 2.5 mL in 24 hours
Children under 2 years of age
  • Do not use
Consumers with kidney disease
  • Do not use

Use as directed; see full Drug Facts label.

Download the full
Drug Facts label
Download the full Medication Guide